Journal
ONCOTARGET
Volume 7, Issue 36, Pages 57851-57865Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.11072
Keywords
plexin; anti-cancer drug; angiogenesis; biomarker; glioblastoma
Categories
Funding
- French government
- ANR Interference TM
- Fondation pour la Recherche Medicale (FRM/Rotary International)
- ANR Interference TM project [ANR-10-BLAN-1507]
- Agence Nationale de la Recherche (ANR) [ANR-10-BLAN-1507] Funding Source: Agence Nationale de la Recherche (ANR)
Ask authors/readers for more resources
The neuropilin-plexin receptor complex regulates tumor cell migration and proliferation and thus is an interesting therapeutic target. High expression of neuropilin-1 is indeed associated with a bad prognosis in glioma patients. Q-RTPCR and tissue-array analyses showed here that Plexin-A1 is highly expressed in glioblastoma and that the highest level of expression correlates with the worse survival of patients. We next identified a developmental and tumor-associated pro-angiogenic role of Plexin-A1. Hence, by using molecular simulations and a two-hybrid like assay in parallel with biochemical and cellular assays we developed a specific Plexin-A1 peptidic antagonist disrupting transmembrane domain-mediated oligomerization of the receptor and subsequent signaling and functional activity. We found that this peptide exhibits anti-tumor activity in vivo on different human glioblastoma models including glioma cancer stem cells. Thus, screening Plexin-A1 expression and targeting Plexin-A1 in glioblastoma patients exhibit diagnostic and therapeutic value.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available